Why Innovaccer Prefers Private Maneuvers Over Going Public

Renowned healthcare AI startup, Innovaccer, is on a mission to bolster its portfolio with a few more acquisitions on the horizon. However, an IPO is noticeably absent from its agenda.

With over a decade of operations, the company is extending its presence in private markets, opting for secondary transactions while enhancing its array of healthcare AI applications.

Earlier this year, Innovaccer secured $275 million, where close to $100 million involved selling shares from early investors. Following this, employees benefited from a $50 million offer backed by Series F investors.

"At this maturity level, such development is predictable," remarked Innovaccer's co-founder and CEO, Abhinav Shashank. "The rapidly changing business landscape gives us the latitude for long-term strategies in private sectors far exceeding what public options present."

This sentiment is echoed across venture-backed firms facing a challenging IPO climate. While some digital health companies floated shares successfully, many fell short compared to the larger market scenario. Presently, it is expected that companies aiming for IPOs must demonstrate strong financial metrics.

Innovaccer's recent valuation places it at $3.45 billion. According to Shashank, the firm is rapidly meeting these benchmarks, with revenue growth exceeding 40% and operating cash positive, although current revenue figures remain undisclosed.

With abundant resources at its disposal within private spheres, Innovaccer is under no urgency to pursue an IPO. The primary driver for potentially raising more funds pertains mainly to its plans for mergers and acquisitions.

Acquisition Goals and Strategies

Innovaccer's foundational goal was to create technological frameworks to unify varied health data sources. With the proliferation of AI, it aims to facilitate seamless interaction among AI solutions within healthcare settings.

The platform encompasses varied services including AI call center support, financial management software, and tech for deciphering population health, with future additions anticipated.

The aim, says Shashank, is for Innovaccer to be the all-in-one solution hub, bypassing the need for multiple point solutions, which require additional investments in integration.

Despite the comprehensive tech offerings, Innovaccer faces stiff competition from entities like Health Catalyst and startups evaluated in the billions.

Focusing on acquisitions to spur growth, the firm prioritizes technologies that would streamline hospital administration and automated healthcare management. Remote patient oversight and automation in care management also form acquisition targets.

Already having executed three acquisitions including recent ones in 2024, Innovaccer positions itself for more with significant financial reserves, aiming to leverage its expansive reach across vast health systems.

Moreover, Innovaccer aspires to enhance its client offerings through partnerships, planning a marketplace with numerous companies tailored into its structure to enable seamless third-party tool integration.

Is Public Listing Necessary?

While giants like OpenAI reap substantial investor returns through private dealings, the necessity of going public is a debatable topic among board members, according to Shashank.

Private market ventures provide the freedom to make large-scale acquisitions without the constraints of public investor judgment. Innovative firms like Databricks and Stripe exemplify growth and investor liquidity through private secondary markets.

Even though Shashank acknowledges the long-term benefits of public markets, he signals that an IPO is not imminent. Innovaccer is poised to address public listings when circumstances align.

In light of thriving secondary sales mainly enjoyed by leading AI and software entities, Innovaccer's aim is to expand until achieving robust recurring revenue figures prior to any public share offerings.

"We're active on various fronts currently, suggesting an IPO is likely a few years away," Shashank noted.